Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): A multicentre phase IIb randomised active-controlled clinical trial

BMJ Open

Volumn 5, Issue 9, 2015, Pages

  Sivaprasad, Sobha ^a   Prevost, A Toby ^b   Bainbridge, James ^c   Edwards, Rhiannon Tudor ^d   Hopkins, David ^e   Kelly, Joanna ^b   Luthert, Phil ^c   Murphy, Caroline ^b   Ramu, Jayashree ^a   Sarafraz Shekary, Negin ^b   Vasconcelos, Joana ^b   White Alao, Beverley ^b   Hykin, Philip ^a  

^a Moorfields NIHR Ophthalmology Biomedical Research Centre   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d BANGOR UNIVERSITY   (United Kingdom)

^e KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; PLACENTAL GROWTH FACTOR; VASCULOTROPIN A; VASCULOTROPIN B; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PROLIFERATIVE DIABETIC RETINOPATHY; RANDOMIZED CONTROLLED TRIAL; RETINA NEOVASCULARIZATION; SINGLE BLIND PROCEDURE; VISION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MULTICENTER STUDY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84947923928     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-008405     Document Type: Article

References (25)

1. Abbate M, Cravedi P, Iliev I, et al. Prevention, and treatment of diabetic retinopathy: evidence from clinical trials, and perspectives. Curr Diabetes Rev. 2011; 7: 190-200.
2. [No authors listed]. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98(5 Suppl): 766-85.
3. [No authors listed]. Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1976; 81: 383-96.
4. Stefánsson E. Ocular oxygenation, and the treatment of diabetic retinopathy. Surv Ophthalmol. 2006; 51: 364-80.
5. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol. 2003; 136: 122-35.
6. Bailey CC, Sparrow JM, Grey RH, et al. The National Diabetic Retinopathy Laser Treatment Audit. III. Clinical outcomes. Eye (Lond) 1999; 13: 151-9.
7. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification, and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med. 1995; 1: 182-93.
8. Lange CA, Stavrakas P, Luhmann UF, et al. Intraocular oxygen distribution in advanced proliferative diabetic retinopathy. Am J Ophthalmol. 2011; 152: 406-12.
9. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally, and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994; 145: 574-84.
10. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy, and other retinal disorders. N Engl J Med. 1994; 331: 1480-7.
11. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-Associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996; 114: 66-71.
12. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995; 92: 10457-61.
13. Ip MS, Domalpally A, Hopkins JJ, et al. Long-Term effects of ranibizumab on diabetic retinopathy severity, and progression. Arch Ophthalmol. 2012; 130: 1145-52.
14. Salam A, D'Costa J, Sivaprasad S. Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta Ophthalmol. 2011; 89: 405-11.
15. Martin DF, Maguire MG, Fine SL, et al, Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab, and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results, Ophthalmology. 2012; 119: 1388-98.
16. Rosser DA, Cousens SN, Murdoch IE, et al. How sensitive to clinical change are ETDRS logMAR visual acuity measurements' Invest Ophthalmol Vis Sci. 2003; 44: 3278-81.
17. Chakravarthy U, Harding SP, Rogers CA, et al, IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012; 119: 1399-411. Erratum in: Ophthalmology 2012 Aug; 119(8): 1508. Ophthalmology. 2013; 120 (9): 1719.
18. González VH, Giuliari GP, Banda RM, et al. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. Br J Ophthalmol. 2009; 93: 1474-8.
19. Mangione CM, Lee PP, Gutierrez PR, et al, National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001; 119: 1050-8.
20. Brose LS, Bradley C. Psychometric development of the individualized Retinopathy-Dependent Quality of Life Questionnaire (RetDQoL). Value Health. 2010; 13: 119-27.
21. Brose LS, Bradley C. Psychometric development of the retinopathy treatment satisfaction questionnaire (RetTSQ). Psychol Health Med. 2009; 14: 740-54.
22. Janssen MF, Birnie E, Bonsel GJ. Quantification of the level descriptors for the standard EQ-5D three-level system, and a five-level version according to two methods. Qual Life Res. 2008; 17: 463-73.
23. Al-Janabi H, Peters TJ, Brazier J, et al. An investigation of the construct validity of the ICECAP-A capability measure. Qual Life Res. 2013; 22: 1831-40.
24. Council MR A framework for development, and evaluation of RCT. BMJ. 2009; 339: b3496.
25. Edwards RT, Ceilleachair A, Bywater T, et al. Parenting programme for parents of children at risk of developing conduct disorder: cost effectiveness analysis. BMJ. 2007; 334: 682-5.